Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Yuting Yan, Xiaoqi Qin, Lanting Liu, Shuhui Deng, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Fu Mingwei, MD, Xue-Han Mao, MD, Zhen Yu, MD, Dehui Zou, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143447

Published: 2020

Journal Articles

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Chenxing Du, MD, Xue-Han Mao, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, MD, Wenyang Huang, Yan Xu, Chengwen Li, Jiawei Zhao, Dehui Zou, MD, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140909

Published: 2020

Journal Articles

Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Blood (2020) 136 (Supplement 1): 38–41.

https://doi.org/10.1182/blood-2020-136108

Published: 2020

Journal Articles

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial

Gang An, MD PhD, Daobin Zhou, MD PhD, Weili Zhao, MD PhD, Keshu Zhou, MD PhD, Jianyong Li, MD PhD, Jianfeng Zhou, MD PhD, Liping Xie, MD PhD, Jie Jin, MD PhD, Liye Zhong, MD PhD, Lingzhi Yan, MD PhD, Haiyi Guo, MD, Chenmu Du, MD, Jane Huang, MD, William Novotny, MD, Jinhua Zhong, PhD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136783

Published: 2020

Journal Articles

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-138734

Published: 2020

Journal Articles

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Ryu Lv, Yi Wang, Tingyu Wang, Xiong Wenjie, Huijun Wang, Yuting Yan, Qi Wang, Wei Liu, Gang An, MD PhD, Wenyang Huang, Weiwei Sui, MD, Yan Xu, MD, Zhen Yu, MD, Dehui Zou, MD, Jianxiang Wang, MD, Lugui Qiu, MD, Shuhua Yi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-138592

Published: 2020

Journal Articles

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Chenxing Du, MD, Yi Wang, Xue-Han Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Yan Xu, Weiwei Sui, MD, Shuhui Deng, MD, Fu Mingwei, MD, Chengwen Li, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Yaozhong Zhao, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140718

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

Yi Wang, Jing Zhuang, Gang An, MD PhD, Xue-Han Mao, MD, Chenxing Du, MD, Jiahui Liu, Huishou Fan, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-141188

Published: 2020

Journal Articles

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Gang An, MD, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3105.

https://doi.org/10.1182/blood-2019-130927

Published: 2019

Journal Articles

Excess Serine from the Microenvironment Caused the Impaired Megakaryopoiesis and Thrombocytopia in Multiple Myeloma

Chunmei Kuang, Meijuan Xia, Gang An, MD, Cuicui Liu, Dan Wu, Pei Su, Jingyu Zhang, Jiliang Xia, PhD, Jiaojiao Guo, Xuan Wu, Wei Jia, PhD, Lugui Qiu, MD PhD, Wen Zhou, PhD, Jiaxi Zhou

Blood (2019) 134 (Supplement_1): 4331.

https://doi.org/10.1182/blood-2019-125289

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Yuting Yan, Yan Xu, Xuehan Mao, MD, Jiahui Liu, Huishou Fan, Qi Wang, Chenxing Du, Li Zengjun, Shuhua Yi, MD, Rui Lv, Shuhui Deng, MD, Weiwei Sui, Mu Hao, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Gang An, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4405.

https://doi.org/10.1182/blood-2019-124096

Published: 2019

Journal Articles

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Blood (2018) 132 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2018-99-118994

Published: 2018

Journal Articles

APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, BS, Tengteng Yu, MD, Phillip Hsieh, Gang An, MD, Lugui Qiu, MD PhD, Nikhil Munshi, MD, Kenneth Anderson, MD, Yu-Tzu Tai, PhD

Blood (2018) 132 (Supplement 1): 407.

https://doi.org/10.1182/blood-2018-99-110317

Published: 2018

Journal Articles

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma

Xiaoyan Feng, Chirag Acharya, MD, Gang An, MD PhD, Kenneth Wen, Li Zhang, Alireza Kalbasi, Lugui Qiu, MD, Nikhil C Munshi, MD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 2106.

https://doi.org/10.1182/blood.V128.22.2106.2106

Published: 2016

Journal Articles

Plasma Cell Leukemia in China: Retrospective Analysis of Clinical Characteristics and Prognosis

Tengteng Yu, MD, Yan Xu, MD, PhD, Gang An, MD PhD, Zengjun Li, MD, PhD, Mu Hao, MD, PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 5619.

https://doi.org/10.1182/blood.V128.22.5619.5619

Published: 2016

Journal Articles

Osteoclasts Promote Immune Suppressive Microenvironment in Multiple Myeloma: Therapeutic Implication

Gang An, MD PhD, Chirag Acharya, Xiaoyan Feng, MD, Kenneth Wen, Mike Zhong, BS, Li Zhang, Nikhil C Munshi, MD, Lugui Qiu, MD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 3303.

https://doi.org/10.1182/blood.V128.22.3303.3303

Published: 2016

Journal Articles

SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide

Hua Jiang, MDPhD, Gang An, MD PhD, Chirag Acharya, MD, Mike Y Zhong, BS, Ti Cai, PhD, Zhili Song, Guang Yang, Francisco Adrian, PhD, Nikhil C. Munshi, MD, Yu-Tzu Tai, PhD, Kenneth C. Anderson

Blood (2014) 124 (21): 2124.

https://doi.org/10.1182/blood.V124.21.2124.2124

Published: 2014

Journal Articles

MiR-137 Contributes to Drug Susceptibility and Chromosomal Instability of Multiple Myeloma through Targeting AURKA

Yu Qin, PhD, Fei Li, MD, Xiaoqi Qin, Gang An, MD PhD, Mu Hao, PhD, Meirong Zang, PhD, Yan Xu, MD PhD, Wen Zhou, PhD, Hong Chang, Lugui Qiu, MD

Blood (2014) 124 (21): 5715.

https://doi.org/10.1182/blood.V124.21.5715.5715

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Excess Serine from the Microenvironment Caused the Impaired Megakaryopoiesis and Thrombocytopia in Multiple Myeloma

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma

Plasma Cell Leukemia in China: Retrospective Analysis of Clinical Characteristics and Prognosis

Osteoclasts Promote Immune Suppressive Microenvironment in Multiple Myeloma: Therapeutic Implication

SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide

MiR-137 Contributes to Drug Susceptibility and Chromosomal Instability of Multiple Myeloma through Targeting AURKA

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only